B-cell Responses to Pneumococcal Vaccination in HIV-infected patients
Research type
Research Study
Full title
B-cell Immune Responses to Pneumococcal Vaccination in HIV-infected patients
IRAS ID
199291
Contact name
Sian E. Faustini
Contact email
Sponsor organisation
University of Birmingham
Duration of Study in the UK
0 years, 7 months, 9 days
Research summary
This study plans to measure the immune response to vaccination against bacteria called pneumococcus in HIV-infected adults. In particular, we will examine an immune cell called a B-lymphocyte, that produces the antibodies that protect against infection. Studies show that only half of HIV-infected patients have protective antibodies after pneumococcal vaccination and this study is trying to understand why some patients don’t respond by looking at the different types B-lymphocytes, how they are affected by vaccination and whether they produce good quality antibody.
Twenty HIV patients will be recruited from the HIV clinic at the University Hospital Birmingham by clinical staff and researchers associated with the project. Patients will receive a single dose of pneumococcal vaccination (PCV-13) at month 0, as recommended by national guidelines as a standard of care. Patients will have additional study blood taken for immune testing at the time of vaccination, 1-week and 4-weeks later
The blood will be tested to measure the amount of antibody produced to vaccination (standard clinical test) but go on to examine how good these antibodies are at killing pneumococcus and whether B cells that are specific for pneumococcus are produced to understand the quality of the immune response and if antibodies aren’t produced why the vaccine has failed.
REC name
West Midlands - Edgbaston Research Ethics Committee
REC reference
16/WM/0313
Date of REC Opinion
3 Oct 2016
REC opinion
Further Information Favourable Opinion